Danaher (NYSE:DHR) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Danaher (NYSE:DHR) in a research report report published on Friday, Benzinga reports. The brokerage currently has a $300.00 price target on the conglomerate’s stock.

Several other equities analysts have also recently commented on DHR. Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an equal weight rating and a $280.00 target price on the stock. Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They set a buy rating and a $295.00 target price on the stock. TD Cowen upped their target price on Danaher from $290.00 to $310.00 and gave the stock a buy rating in a research report on Wednesday, July 24th. StockNews.com cut Danaher from a buy rating to a hold rating in a research report on Tuesday, June 25th. Finally, Robert W. Baird upped their price objective on Danaher from $271.00 to $278.00 and gave the company an outperform rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $278.94.

Danaher Stock Performance

Shares of NYSE DHR opened at $273.09 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average price is $261.87 and its two-hundred day moving average price is $255.96. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70. The stock has a market capitalization of $197.23 billion, a P/E ratio of 46.29, a P/E/G ratio of 4.38 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the business posted $2.05 earnings per share. As a group, sell-side analysts forecast that Danaher will post 7.59 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. Insiders own 11.10% of the company’s stock.

Hedge Funds Weigh In On Danaher

Institutional investors have recently made changes to their positions in the business. Tsfg LLC boosted its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. nVerses Capital LLC acquired a new stake in Danaher during the second quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher during the second quarter valued at about $25,000. Cape Investment Advisory Inc. acquired a new position in Danaher in the 4th quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the 1st quarter valued at approximately $30,000. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.